Table 2. Hematological, cytogenetic, and molecular responses at different time-points.

Responses	Overall Series n. (%)	Prospective cohort n. (%)	Retrospective cohort n. (%)	Statistical significance
CHR by 3 months
Yes	76 (97%)	29 (100%)	47 (96%)	p=0.392
No	2 (3%)	0	2 (4%)
CCyR by 6 months
Yes	66 (85%)	25 (86%)	41 (84%)	p=0.376
No	12 (15%)	4 (14%)	8 (16%)
CCyR by 12 months
Yes	69 (88.5)	25 (86%)	44 (90%)	p=0.593
No	9 (11.5)	4 (14%)	5 (10%)
EMR
Yes	63 (81%)	28 (96%)	35 (71%)	p=0.012
No	15 (19%)	1 (4%)	14 (29%)
MR3 by 12 months
Yes	60 (77%)	22 (76%)	38 (78%)	p=0.537
No	18 (23%)	7 (24%)	11 (22%)
MR3 (at any time)
Yes	68 (88%)	23 (79%)	45 (92%)	p=0.182
No	10 (12%)	6 (21%)	4 (8%)
DMR (at any time)
Yes	50 (64%)	13 (45%)	37 (76%)	p=0.002
No	28 (36%)	16 (55%)	12 (24%)

Abbreviations: CHR, complete hematological response; CCyR, complete cytogenetic response; EMR, early molecular response; MR3, complete hematological response; DMR, deep molecular response